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Abstract
Purpose The prognosis of patients with pancreatic cancer
remains poor, even after potentially curative R0 resection.
This discrepancy may be due to the histopathological
misclassification of R1 cases as curative resections (R0)
in the past.
Materials and methods To test this hypothesis, color
coding of all resection margins and organ surfaces as part
of a standardized histopathological workup was imple-
mented and prospectively tested on 100 pancreatic head
specimens.
Results Thirty-five patients were excluded from the analysis
owing to the pathohistological diagnosis; only pancreatic
ductal adenocarcinoma, distal bile duct adenocarcinoma, and
periampullary adenocarcinoma were included. Applying the
International Union Against Cancer criteria, 32 cancer
resections were classified R0 (49.2%), while 33 cases turned
out to be R1 resections (50.8%). The mesopancreas
was infiltrated in 22 of the 33 R1 resection specimens
(66.6%). It proved to be the only site of tumor infiltration in
17 specimens (51.5%). Applying the Royal College of
Pathologists’ criteria, 46 resections were classified R1
(70.8%). As expected, the mesopancreas again was the most
frequent site of noncurative resection (n=27; 58.7%).
Conclusion Using the intensified histopathological workup
for pancreatic head cancer specimens resulted in an
increased rate of R1 resections and the mesopancreas
represents the primary site for positive resection margins.
Such results are of relevance for patients’ stratification in
clinical trials.
Keywords Pancreaticcancer.Mesopancreas.
Histopathologicalworkup.R1resection
Introduction
Due to its dismal prognosis, pancreatic cancer is the fourth
most common cause of cancer death in Europe and the
USA. From a clinical point of view, resection status is one
of the major factors influencing patient survival. Therefore,
complete surgical resection of the primary tumor represents
the only curative treatment option.
However, even patients with tumor-free margins (R0
resection) experience frequently local recurrence and
distant metastases, which is in clear contrast to other solid
tumors of the gastrointestinal tract. Consequently, more
radical approaches have been evaluated, first described by
Fortner and colleagues [3]. Even though there was initial
indication of some survival benefit, follow-up studies have
failed to confirm these promising results [9]. This raised the
question as to whether such a discrepancy is caused, other
than through incomplete lymphadenectomy and perineural
invasion, by a misclassification of R1 resections as R0
resections [1]. According to the recent literature, the rates of
noncurative resections range from 15% to 35% [12, 15, 23,
27], whereas postmortem examinations of pancreatic cancer
Langenbecks Arch Surg (2010) 395:451–458
DOI 10.1007/s00423-009-0494-8
J. Gaedcke:M. Grade: R. Szöke:T. Liersch: H. Becker:
B. M. Ghadimi (*)
Department of General and Visceral Surgery,
University Medical Center, Georg-August-University Göttingen,
Robert-Koch-Str. 40,
37075 Göttingen, Germany
e-mail: mghadim@gwdg.de
B. Gunawan
Department of Pathology, University Medical Center,
Georg-August-University Göttingen,
Göttingen, Germanypatients revealed local recurrence rates approaching 100%
[5, 7, 19, 21, 24]. This is supported by recent publications
(Verbeke et al. [22] and Esposito et al. [2]) revealing that
modified histopathological workup of pancreatic head
carcinomas leads to R1 resection rates of 85% and 76%,
respectively.
T h ea i mo ft h ep r e s e n ta r t i c l ew a st od e v e l o pa n
optimized and standardized histopathological workup and
to test prospectively the hypothesis that current histopath-
ological reports underestimate the proportion of R1 pan-
creatic head resections. Towards this goal, we firstly
implemented color coding of the resection margins (RMs)
and the organ surfaces. Secondly, we carefully reevaluated
the different sites of R1 resections according to the color
code and demonstrated that the mesopancreatic RM was the
most frequent site of incomplete tumor resection.
Materials and methods
Retrospective data analysis
In order to test the hypothesis that an optimized and
standardized histopathological workup increases the rate of
R1 resections after pancreatic head resections, we first
compared the rates of curative resections after conventional
histopathological workup in our department. Therefore, we
retrospectively identified all patients who had undergone
pancreatic head resection, either through pylorus-preserving
pancreaticoduodenectomy (PPPD) or Kausch–Whipple pro-
cedure due to malignant diseases, in the Department of
General and Visceral Surgery between 1996 and 2005.
During this period, all specimens were worked up by
pathologists specializing in gastrointestinal pathology. The
location, histological tumor type, size of tumor, and lymph
node involvement were defined. Assessment of the RM
included the common bile duct, the pancreatic transection
margin, the duodenal and jejunal resection plane, and the
anterior and posterior surface. Additionally, vascular,
lymphatic, and perineural invasion were reported if present.
Cases with macroscopic tumor residues at the surgical RM
or the organ surface were defined as R2. If tumor cells at
the surgical RM or the organ surface were only detectable
microscopically, the resection was classified R1. A curative
R0 resection was defined as a surgical RM or organ surface
without tumor cell infiltration.
Establishing a modified histopathological workup
and prospective data analysis
A modified and standardized histopathological workup was
introduced in April 2006 and prospectively tested for
28 months until July 2008. Organ surfaces and RMs of
the pancreatic head resection specimen were stained
according to a well-defined five-color code (Fig. 1): the
anterior (ventral) surface was painted black, the posterior
(dorsal) surface white, the groove of the superior mesen-
teric vein (SMV) green, the pancreatic transection margin
yellow, and the mesopancreas red. The mesopancreas was
defined as the soft tissue between the superior mesenteric
artery and the pancreatic parenchyma and contains lym-
phatic, nervous, and vascular structures. Since its identifi-
cation is challenging, especially after formalin fixation, the
mesopancreas was stained directly after removing the
specimen from the situs, while the other parts were colored
after formalin fixation for 24 to 36 h. All staining
procedures were performed by the operating surgeon or
by a surgeon present during the procedure.
After fixation and staining, the RMs of the proximal
duodenum/stomach, distal duodenum, the common bile duct,
and if present any major vessel (SMV, portal vein) were
identified and completely embedded. The specimen was
serially sliced (0.5- to 1-cm slices) perpendicular to the
mesopancreatic RM (Fig. 2a–c). The pancreatic RM and the
mesopancreas were completely embedded. Several samples
were taken from the tumor with relation to the anterior and
posterior surface. The distance between the tumor and each
colored surface or resection margin was measured micro-
scopically and documented in the pathohistological report.
Histological classification (tumor type, grade of malignancy,
pathological tumor–node–metastasis) was carried out accord-
ing to the current World Health Organization and Interna-
tional Union Against Cancer (UICC) criteria [26]. According
to the UICC criteria, the operation was considered as
potentially curative (R0) if the RMs and organ surfaces
were free of tumor cells, whereas histopathologically verified
tumor cell infiltration was defined as R1 resection. In cases
of macroscopically visible tumor tissue, the resection was
classified R2. Applying the definition of The Royal College
of Pathologists (RCP) [13], the specimens were classified R1
if tumor cells were within 1 mm of the RM. Histopatholog-
ical inclusion criteria were diagnosis of either pancreatic
ductal adenocarcinoma (PDAC), distal bile duct adenocarci-
nomas (DBD), or periampullary adenocarcinoma (PAC).
Surgical procedures
The vast majority of pancreatic head resections were
performed as PPPD. All resection procedures were per-
formed by two experienced surgeons (BMG, HB). Since an
extended lymphadenectomy does not necessarily improve
patient outcome, we rather intended to achieve oncological
radicality through the extended excision of perivascular
tissue around the superior mesenteric artery (SMA). To
achieve this goal, the SMA was approached caudal to the
region of the uncinate process, where a distinct fascia
452 Langenbecks Arch Surg (2010) 395:451–458separates the uncinate from the mesocolon. Then, the SMA
was isolated laterally right up to the vessel, and all tissues
between the artery and the pancreatic parenchyma were
resected. Attention was paid not to dissect it entirely from
the surrounding mesenteric plexus to avoid postoperative
diarrhea (see Fig. 3). Subsequently, the peripancreatic tissue
was dissected up to the portal vein. Lymph node dissection
was performed up to the hepatoduodenal ligament laterally to
the portal vein. Where there was evidence of tumor
infiltration, the SMV was partially resected and reconstructed
either by end-to-end anastomosis or insertion of a venous
graft. Finally, the posterior surface of the pancreatic head
specimen was assessed macroscopically for its integrity.
Results
In order to compare the rates of curative and noncurative
resections in our department to the published data, we
retrospectively identified 115 patients with malignant
pancreatic head tumors who had undergone either PPPD
or a Kausch–Whipple procedure between 1996 and 2005
(n=115). For 89 of these 115 patients (77.4%), the
operation could be considered potentially curative, whereas
the RMs of 26 cancer specimens were positive (22.6%).
In April 2006, we introduced the modified and stan-
dardized histopathological workup and applied it prospec-
tively until July 2008. During this 28-month period, 100
consecutively resected pancreatic head specimens were
processed according to this protocol. Only five patients
underwent a Kausch–Whipple procedure: three patients as a
consequence of advanced disease, one owing to inflamma-
tory changes of the tissue, and one owing to the intra-
operative detection of a synchronous gastric neoplasia. The
remaining 95 patients were treated with PPPD. For 17
patients, the operation included partial or complete resec-
tion of the SMV. The vena cava was partially removed
once. None of the 100 patients died within 30 days after
Fig. 1 a–d Stained surfaces of
pancreatic head resection speci-
men (black—ventral; white—
dorsal; yellow—pancreatic RM;
green—groove of superior mes-
enteric vein; red—mesopancre-
atic RM)
Langenbecks Arch Surg (2010) 395:451–458 453surgery. A 79-year-old patient who underwent head
resection for ductal adenocarcinoma developed endocarditis
with consecutive mitral valve regurgitation. He required
replacement of the mitral valve but died postoperatively as
a result of the cardiac procedure. The remaining 99 patients
were discharged from hospital.
After definitive histopathological assessment, 35 patients
were excluded from this analysis, owing to histopatholog-
ical diagnosis as listed in Table 1.
Therefore, 65 pancreatic head resections with a malig-
nant tumor were analyzed further (PAC, n=7; DBD, n=12;
PDAC, n=46). Applying the UICC criteria, 32 cancers
were curatively (R0) resected (49.2%), while 33 cases
turned out to be R1 resections (50.8%; Table 2). Seven
R1 resections revealed tumor infiltration in two stained
areas. Interestingly, the mesopancreas was the only site of
infiltration in 17 of these R1 specimens (51.5%). In
another five cases, infiltration of the mesopancreas with
additional involvement of the SMV or the pancreatic
transection margin was discovered. In all, the mesopan-
creas was determined as being the most frequent site with
residual tumor mass by far (n=22, 56.4%). The groove of
the SMV (n=1), the anterior (n=2) and posterior surface
(n=1), the pancreatic transection margin (n=4), and the
proximal duodenum (n=2) were only infiltrated infre-
quently in the final histological diagnosis. SMV margins
were infiltrated in seven of the 17 specimens including
partial or complete SMV resection. Applying the defini-
tions of the RCP, an additional set of 13 specimens would
have to be considered as R1 resections, resulting in a total
percentage of 70.8% of noncurative operations. As
expected, the total number of affected areas increased
from 39 to 83, involving the mesopancreas (n=27) and the
anterior (n=18) and the posterior (n=13) surface most
often (Table 2).
PDAC represent 71% of all analyzed cancer specimens.
Looking at each histopathological type, it became obvious
that the number of R1 resections is much lower for DBD
Fig. 2 Section planes indicated
at resection specimen (a). Indi-
vidual slices (b) and magnifica-
tion of one representative slice
(c). AC indicates the adenocar-
cinoma, MP the mesopancreas
454 Langenbecks Arch Surg (2010) 395:451–458(16.7% or 41.7% applying UICC or RCP criteria) and PAC
(28.6% or 42.9%), irrespective of the classification.
Although the total number of R1 resected specimens is
too small to draw definitive conclusions, it is noteworthy
that the mesopancreas is infiltrated in two of the two R1
resected PAC.
Discussion
Cancer of the pancreatic head is one of the most malignant
gastrointestinal tumors. Surgery is still considered to be the
only potentially curative approach if complete resection is
possible [6, 20, 23]. However, surgical resection in patients
with localized pancreatic cancer is still underused [14].
Retrospective analyses of data from patients treated in our
department between 1996 and 2005 revealed a 5-year
survival rate of 20% for R0 patients, which is in agreement
with the literature, even though some authors deny the
existence of 5-year survivors [4]. With respect to the
classification of the pancreatic head resections evaluated
retrospectively, the percentage of R1 resections (22.6%)
also mirrors the literature [12, 15, 23, 27]. These data
appear to indicate the possible misclassification of R1
resections as R0.
Local recurrence and disseminated cancer spread dra-
matically impair the prognosis of patients with pancreatic
head cancer. This is supported by postmortem examinations
reporting a local recurrence rate approaching 100% [5, 7,
19, 21, 24]. Luettges et al. [8, 13] already stated in 1999
that tumor recurrence is primarily due to incomplete
removal at the site of resection rather than to metastatic
disease. They pointed out that the retroperitoneal RM has
an influence on patient survival. However, it was in 2006
when Verbeke et al. [22] first reported an incomplete
resection rate of 85% using a standardized and intensified
No. Nonmalignant or borderline No. Malignant
7 Chronic pancreatitis 5 Neuroendocrine tumor
4 Autoimmune pancreatitis 4 Metastases to the pancreatic head
2 Periampullary adenoma 1 Duodenal adenocarcinoma
2 Periampullary adenomyoma 1 Acinar cell carcinoma
2 Serous cystadenoma 1 Non-Hodgkin lymphoma
2 Intraductal papillary mucinous neoplasia (IPMN)
1 Mucinous cystadenoma
1 Duodenitis
1 Simple pancreatic cyst
1 Duodenal diverticulum
23 Total 12 Total
Table 1 Pancreatic head speci-
mens excluded from analysis
Fig. 3 Intraoperative view be-
fore (left) and after resection of
the mesopancreas (right). Small
arrows point to the superior
mesenteric artery; large arrow
indicates the resection line;
dashed line indicates dissection
plane (left; SMV—superior mes-
enteric vein; SMA—superior
mesenteric artery; PV—portal
vein)
Langenbecks Arch Surg (2010) 395:451–458 455workup. For the 54 pancreatic head resections, a color code
was implemented to distinguish between the anterior,
posterior, and SMV groove surface. Similar results were
published by Esposito et al. [2] who reported an R1
resection rate of 76% in 111 PDAC. As part of their
protocol, they color-coded the anterior, posterior, medial
margin, and groove surface of the SMV, respectively,
whereas the retroperitoneal RM was not investigated
separately. The importance of the retroperitoneal resection
margin was confirmed by Westgaard et al. [25]w h o
thoroughly worked up 114 periampullary adenocarcinomas
by perpendicular sectioning. The overall R1 resection rate
was 35%, whereas the retroperitoneal resection margin was
involved in 80% of the specimens. However, it should be
pointed out that all three studies classified the specimens
according to the definition of The Royal College of
Pathologists. Since there do not exist any general guidelines
about the definition of R1 resection, we primarily applied
the UICC criteria, i.e., a curative resection was defined as
there being no microscopic evidence of residual tumor at
the RM. We found an R1 resection rate of 50.8%, which
demonstrates that a high rate of R1 resections is not only
based on the definition of margin positivity as tumor
clearance of ≤1 mm.
Our R1 rate (using RCP criteria) was comparable to
those from Verbeke et al. [22] and Esposito et al. [2].
Therefore, we could confirm that the number of noncurative
resections is considerably higher when a modified and
intensified histopathological workup is applied. Interesting-
ly, Westgaard et al. [25] only investigated the transection
margins of the pancreas and reached R1 rate of 45% for
PDAC and 59% for DBD. The anterior or posterior surfaces
of the pancreas were not part of the workup.
We identified the mesopancreas as the primary site of
positive RMs. In total, 66.6% of those cancers resected
noncuratively displayed infiltration of this structure. As
Table 2 Histopathological and resection classification data
All cancers PDAC DBD PAC
UICC RCP UICC RCP UICC RCP UICC RCP
Resection
R0 32 (49.2%) 19 (29.2%) 17 (37.0%) 8 (17.4%) 10 (83.3%) 7 (58.3%) 5 (71.4%) 4 (57.1%)
R1/R2 33 (50.8%) 46 (70.8%) 29 (63.0%) 38 (82.6%) 2 (16.7%) 5 (41.7%) 2 (28.6%) 3 (42.9%)
Site of R1
Mesopancreas 22 (56.4%) 27 (32.5%) 19 (57.6%) 24 (34.3%) 1 (25.0%) 1 (11.1%) 2 (100%) 2 (50.0%)
Pancreatic transection margin 4 (10.3%) 11 (13.3%) 3 (9.1%) 10 (14.3%) 1 (25.0%) 1 (11.1%) 0 0
Anterior 2 (5.1%) 18 (21.7%) 2 (6.1%) 15 (21.4%) 0 1 (11.1%) 0 2 (50.0%)
Posterior 1 (2.6%) 13 (15.7%) 1 (3.0%) 11 (15.7%) 0 2 (22.2%) 0 0
Groove of SMV 1 (2.6%) 4 (4.8%) 1 (3.0%) 2 (2.9%) 0 2 (22.2%) 0 0
SMV (n=17) 7 (17.9%) 8 (9.6%) 5 (15.2%) 6 (8.6%) 2 (50.0%) 2 (22.2%) 0 0
Duodenum oral 2 (5.1%) 2 (2.4%) 2 (6.1%) 2 (2.9%) 0 0 0 0
Number of infiltrated sites
1 26 (78.8%) 22 (47.8%) 25 (86.2%) 18 (47.4%) 0 2 (40%) 2 (100%) 2 (66.7%)
2 7 (21.2%) 14 (30.4%) 4 (13.8%) 11 (28.9%) 2 (100%) 2 (40%) 0 1 (33.3%)
3 0 8 (17.4%) 0 7 (18.4%) 0 1 (20%) 0 0
4 0 1 (2.2%) 0 1 (2.6%) 0 0 0 0
5 0 1 (2.2%) 0 1 (2.6%) 0 0 0 0
Total 39 83 33 70 4 9 2 4
T1 2 (3.1%) 2 (4.3%) 0 0
T2 1 (1.5%) 0 0 1 (14.3%)
T3 50 (76.9%) 43 (93.5%) 6 (50%) 1 (14.3%)
T4 12 (18.5%) 1 (2.2%) 6 (50%) 5 (71.4%)
N0 12 (18.5%) 7 (15.2%) 4 (33.3%) 1 (14.3%)
N1 53 (81.5%) 39 (84.8%) 8 (66.7%) 6 (85.7%)
Resection of 13 PDAC and four DBD included an SMV resection
UICC International Union Against Cancer, RCP Royal College of Pathologists, SMV superior mesenteric vein, PDAC pancreatic ductal
adenocarcinoma, DBD distal bile duct adenocarcinoma, PAC periampullary adenocarcinoma
456 Langenbecks Arch Surg (2010) 395:451–458pointed out by other authors [8, 25] the retroperitoneal RM
is of great interest with regard to curative resection.
Interestingly, there is no exact definition of the retroperito-
neal RM. Some consider the complete posterior surface of
the pancreas as retroperitoneal margin, while others use the
term to describe just the area of sharp dissection, similar to
what we call mesopancreatic RM. Esposito et al. [2]
defined medial and posterior soft tissue margins to
acknowledge the importance of the region. This diversity
of definitions impairs a meaningful comparison of RMs.
Therefore, we introduced the term “mesopancreatic RM” to
describe the dissection margin in the peripancreatic fatty
tissue behind the pancreatic head and lateral to the
mesenteric artery. It was chosen because of its anatomical
origin and therapeutic implication. The tissue between the
pancreatic parenchyma and the SMA consists of fatty tissue
and contains blood and lymphatic vessels, as well as lymph
nodes draining the pancreatic head and the uncinate.
Additionally, nerve fibers are located in the mesopancreas
innervating the pancreatic parenchyma. In this context,
these structures should be defined as mesopancreas
although the peritoneal attachment, which is a requisite to
the existence of a “meso” [10], was lost during embryo-
logical development owing to duodenal rotation. The
mesopancreas rises from the embryological mesentery
attaching the pancreatic bud to the abdominal wall. This
leads to the consequence that the mesopancreas must be
resected and removed completely in its integrity down to
the mesenteric artery. Based on the embryological devel-
opment and according to our experience, the pancreatic
tissue is not directly adjacent to the mesenteric artery but
connected by a delicate meshwork of connective tissue rich
in nerve fibers (mesenteric plexus). This layer should be
separated close to the mesopancreas to prevent the
complications of postoperative diarrhea.
As Verbeke and colleagues demonstrated [22], intensive
embedding of resected tissue increases the rate of R1
resections. However, infiltration of the mesopancreas may
have been misinterpreted in the past as a consequence of a
cancer-induced fibrosis or disseminated cancer cells. There-
fore, RMs in their integrity and numerous samples from the
tumor with relation to the surfaces of the pancreas were
embedded as part of this modified and standardized
protocol.
It is widely accepted that only an R0 resection is
considered as a curative approach and stratification for
resection status is routinely performed in clinical trials such
as in the CONKO-001 trial. Numerous trials failed to show
significant differences in patients’ treatment which could
possibly be due to the misinterpretation of the resection
status based on the lack of a standardized workup [17]. In
general, R1 resections rates of about 20% are reported [11,
16, 18, 27]. However, one can speculate that in these trials
the low R1 resection rates are due to a conventional
pathohistological workup. Being aware of the crucial
importance of assessing the resection rate an intensified
workup is obligatory in trials such as CONKO-005 and
CONKO-006. Considering the mesopancreas as a structure
guiding relevant vessels for lymphatic and blood drainage
of the pancreatic head and the uncinate, it may be
hypothesized that tumor cells drain into the lymphatic and
blood vessels during manipulation of the pancreatic head
(e.g., Kocher’s maneuver). As in the treatment of colorectal
cancer, a no-touch technique would diminish this potential
influence, resulting in the need to resect the mesopancreas
along the superior mesenteric artery first.
Based on our data, we propose a standardized histopath-
ological workup for pancreatic head cancer specimens,
which may represent a more accurate assessment of
curative and noncurative resection rates. As a consequence
of this modified protocol, we demonstrate that the meso-
pancreas is a frequent site for positive resection margins,
which has potential therapeutic implications and should be
considered in clinical trials when stratifying patients into
R0 and R1 resection classifications. Owing to morpholog-
ical changes during formalin fixation, it is of upmost
importance to color the mesopancreatic RM directly after
surgical resection. We strongly believe that the complete
and meticulous surgical resection of the mesopancreas as
the structure to the right of the mesenteric artery must
become the standard surgical approach in pancreatic head
resection.
Acknowledgment The authors thank J. Eggert and L. Schroeter for
technical support.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Buchler MW, Kleeff J, Friess H (2007) Surgical treatment of
pancreatic cancer. J Am Coll Surg 205:S81–S86. doi:10.1016/j.
jamcollsurg.2007.06.332
2. Esposito I, Kleeff J, Bergmann F, Reiser C, Herpel E, Friess H,
Schirmacher P, Buchler MW (2008) Most pancreatic cancer
resections are R1 resections. Ann Surg Oncol 15:1651–1660.
doi:10.1245/s10434-008-9839-8
3. Fortner JG (1973) Regional resection of cancer of the pancreas: a
new surgical approach. Surgery 73:307–320
4. Gudjonsson B (2002) Survival statistics gone awry: pancreatic
cancer, a case in point. J Clin Gastroenterol 35:180–184.
doi:10.1097/00004836-200208000-00011
5. Hishinuma S, Ogata Y, Tomikawa M, Ozawa I, Hirabayashi K,
Igarashi S (2006) Patterns of recurrence after curative resection of
pancreatic cancer, based on autopsy findings. J Gastrointest Surg
10:511–518. doi:10.1016/j.gassur.2005.09.016
Langenbecks Arch Surg (2010) 395:451–458 4576. Jarufe NP, Coldham C, Mayer AD, Mirza DF, Buckels JA, Bramhall
SR (2004) Favourable prognostic factors in a large UK experience
of adenocarcinoma of the head of the pancreas and periampullary
region. Dig Surg 21:202–209. doi:10.1159/000079346
7. Kayahara M, Nagakawa T, Ueno K, Ohta T, Takeda T, Miyazaki I
(1993) An evaluation of radical resection for pancreatic cancer
based on the mode of recurrence as determined by autopsy and
diagnostic imaging. Cancer 72:2118–2123. doi:10.1002/1097-
0142(19931001)72:7<2118::AID-CNCR2820720710>3.0.CO;2-4
8. Luttges J, Vogel I, Menke M, Henne-Bruns D, Kremer B, Kloppel G
(1998) The retroperitoneal resection margin and vessel involvement
are important factors determining survival after pancreaticoduode-
nectomy for ductal adenocarcinoma of the head of the pancreas.
Virchows Arch 433:237–242. doi:10.1007/s004280050242
9. Michalski CW, Kleeff J, Wente MN, Diener MK, Buchler MW,
Friess H (2007) Systematic review and meta-analysis of standard
and extended lymphadenectomy in pancreaticoduodenectomy for
pancreatic cancer. Br J Surg 94:265–273. doi:10.1002/bjs.5716
10. Morgado PJ (1998) Total mesorectal excision: a misnomer for a
sound surgical approach. Dis Colon Rectum 41:120–121.
doi:10.1007/BF02236909
11. Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA,
Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F,
Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW
(2004) A randomized trial of chemoradiotherapy and chemother-
apy after resection of pancreatic cancer. N Engl J Med 350:1200–
1210. doi:10.1056/NEJMoa032295
12. Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K,
Schramm H, Fahlke J, Zuelke C, Burkart C, Gutberlet K, Kettner
E, Schmalenberg H, Weigang-Koehler K, Bechstein WO,
Niedergethmann M, Schmidt-Wolf I, Roll L, Doerken B, Riess
H (2007) Adjuvant chemotherapy with gemcitabine vs observa-
tion in patients undergoing curative-intent resection of pancreatic
cancer: a randomized controlled trial. JAMA 297:267–277.
doi:10.1001/jama.297.3.267
13. The Royal College of Pathologists (2002) Standards and mini-
mum datasets for reporting cancers. Minimum dataset for the
histopathological reporting of pancreatic, ampulla of Vater and
bile duct carcinoma. The Royal College of Pathologists, London
14. Riall TS, Lillemoe KD (2007) Underutilization of surgical
resection in patients with localized pancreatic cancer. Ann Surg
246:181–182. doi:10.1097/SLA.0b013e31811eaa2c
15. Richter A, Niedergethmann M, Sturm JW, Lorenz D, Post S,
Trede M (2003) Long-term results of partial pancreaticoduode-
nectomy for ductal adenocarcinoma of the pancreatic head:
25-year experience. World J Surg 27:324–329. doi:10.1007/
s00268-002-6659-z
16. Schmidt CM, Powell ES, Yiannoutsos CT, Howard TJ, Wiebke
EA, Wiesenauer CA, Baumgardner JA, Cummings OW, Jacobson
LE, Broadie TA, Canal DF, Goulet RJ Jr, Curie EA, Cardenes H,
Watkins JM, Loehrer PJ, Lillemoe KD, Madura JA (2004)
Pancreaticoduodenectomy: a 20-year experience in 516 patients.
Arch Surg 139:718–725. doi:10.1001/archsurg.139.7.718 discus-
sion 725–717
17. Smeenk HG, van Eijck CH, Hop WC, Erdmann J, Tran KC,
Debois M, van Cutsem E, van Dekken H, Klinkenbijl JH, Jeekel J
(2007) Long-term survival and metastatic pattern of pancreatic
and periampullary cancer after adjuvant chemoradiation or
observation: long-term results of EORTC trial 40891. Ann Surg
246:734–740. doi:10.1097/SLA.0b013e318156eef3
18. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams
RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD (2000)
Resected adenocarcinoma of the pancreas—616 patients: results,
outcomes, and prognostic indicators. J Gastrointest Surg 4:567–
579. doi:10.1016/S1091-255X(00)80105-5
19. Sperti C, Pasquali C, Piccoli A, Pedrazzoli S (1997) Recurrence
after resection for ductal adenocarcinoma of the pancreas. World J
Surg 21:195–200. doi:10.1007/s002689900215
20. Stojadinovic A, Brooks A, Hoos A, Jaques DP, Conlon KC,
Brennan MF (2003) An evidence-based approach to the surgical
management of resectable pancreatic adenocarcinoma. J Am Coll
Surg 196:954–964. doi:10.1016/S1072-7515(03)00010-3
21. Takahashi S, Ogata Y, Miyazaki H, Maeda D, Murai S, Yamataka
K, Tsuzuki T (1995) Aggressive surgery for pancreatic duct cell
cancer: feasibility, validity, limitations. World J Surg 19:653–659.
doi:10.1007/BF00294750
22. Verbeke CS, Leitch D, Menon KV, McMahon MJ, Guillou PJ,
Anthoney A (2006) Redefining the R1 resection in pancreatic
cancer. Br J Surg 93:1232–1237. doi:10.1002/bjs.5397
23. Wagner M, Redaelli C, Lietz M, Seiler CA, Friess H, Buchler
MW (2004) Curative resection is the single most important factor
determining outcome in patients with pancreatic adenocarcinoma.
Br J Surg 91:586–594. doi:10.1002/bjs.4484
24. Westerdahl J, Andren-Sandberg A, Ihse I (1993) Recurrence of
exocrine pancreatic cancer-local or hepatic? Hepatogastroenterol-
ogy 40:384–387
25. Westgaard A, Tafjord S, Farstad IN, Cvancarova M, Eide TJ,
Mathisen O, Clausen OP, Gladhaug IP (2008) Resectable
adenocarcinomas in the pancreatic head: the retroperitoneal
resection margin is an independent prognostic factor. BMC
Cancer 8:5. doi:10.1186/1471-2407-8-5
26. Wittekind C, Klimpfinger M, Sobin LH (2005) UICC: TNM
Atlas. Illustrierter Leitfaden zur TNM/pTNM-Klassifikation
maligner Tumoren. Springer, Berlin
27. Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Talamini
MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Zahurak ML,
Grochow LB, Abrams RA (1997) Six hundred fifty consecutive
pancreaticoduodenectomies in the 1990s: pathology, complica-
tions, and outcomes. Ann Surg 226:248–257. doi:10.1097/
00000658-199709000-00004
458 Langenbecks Arch Surg (2010) 395:451–458